Mehr, Pouya E.
Ortiz, Pedro J.
O’Rourke, Kaitlyn R.
Ding, Tan
Hackstadt, Amber J.
Kulapatana, Surat
Diedrich, André
Claassen, Daniel O.
Biaggioni, Italo
Peltier, Amanda C.
Shibao, Cyndya A. https://orcid.org/0000-0002-4518-6801
Funding for this research was provided by:
NIH (R01HL159203, K24HL165163, R01HL161095, R01HL144568, U01NS122419, UL1TR000445)
Overton and Jeanette Smith Foundation
Article History
Received: 12 December 2024
Accepted: 26 April 2025
First Online: 13 May 2025
Declarations
:
: IB and CAS are consultants for Theravance Biopharma. CAS is a member of the scientific board for Antag Therapeutics. Other authors have no conflict of interest.